1.Alternative Name:IL3R,IL-3RA
2.Target:CD123
3.Source:Human CD123 was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence:Thr19-Arg305
5.Protein structure:P26951hFC
6.Molecular Characterization:The protein has a calculated MW of 58kDa.The reducing (R) heterodimer protein migrates as 70-100 kDa due to glycosylation
7.Purity:SDS-PAGE>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg

10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 95%.
12.ELISA

When Recombinant Human CD123/hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human IL-3RA(Pivekimab) that produces 50% of the optimal binding response is approximately 50 ng/ml.
13.SPR

Anti-Human IL-3RA(Pivekimab)（Cat.No.B21679601）captured on CM5 chip , can bind Recombinant Human CD123/hFC Protein（Cat.No.B21677404）with a KD constant of 7.09E-12 M, determined in a SPR assay .

Note：For research use only .